ACE publishes key technical evaluations and processes in scientific journals and often presents scientific content at regional and international symposiums and conferences.
Title
Date of publication
Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore
Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore
October 2020
Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore
Cost-effectiveness analysis of osimertinib for first line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore
September 2020
Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore’s healthcare system perspective
August 2020
Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer
June 2020
Cost-effectiveness analysis of atezolizumab in advanced triple negative breast cancer
Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore
May 2020
Towards greater impact in health technology assessment: horizon scanning for new and emerging technologies in Singapore
Cost effectiveness analysis of bilateral cochlear implants for children with severe-to-profound sensorineural hearing loss in both ears in Singapore
August 2019
Health technology assessment and its use in drug policies: Singapore
May 2019
Cost-effectiveness analysis of sunitinib versus interferon-alfa for first-line treatment of advanced and/or metastatic renal cell carcinoma in Singapore
March 2019
Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
October 2018
Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective
March 2018
Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction
October 2017
Conference
Date